Starpharma granted fast track approval for VivaGel

Company News

by Jessica Amir

Starpharma Holdings Limited, (ASX:SPL) says the FDA has granted a fast track designation as well as a Qualified Infectious Disease Product designation, for its VivaGel product.

VivaGel is used for the treatment and prevention of bacterial vaginoisis in women.

Starpharma has estimated that the market relating to the treatment and prevention of this infection is worth in excess of US$1 billion.

The company says it’s a very positive commercial development which expedites the path to US market entry for VivaGel.

Starpharma posted a net loss of $22.7 million at 30 June 2016.
 

Jessica Amir

Finance News Network
Jessica presents the Market Outlook/Market at Midday and the Market wrap. She also presents ASX company news and interview CEOs. She joined FNN in January 2017. She has been in broadcast journalism for over six years. She has worked as a journalist with Sky News Business, ABC 1, ABC's The Business and ABC24. She has also worked in regional Australia for Prime 7 and WIN News. She has also worked as a qualified financial planner.